Suspension of trading

NeuBase Therapeutics, Inc. Stock Nasdaq

NBSE

US64132K2015

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 23:30:00 10/05/2024 +03			5-day change	1st Jan Change
0.3780 ^USD	-3.20%		-.--%	-

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.11M 1.04M 950K 1.79M 122M 1.82M 12.15M 4.77M 60.82M 4.8M 4.69M 202M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.11M 1.04M 950K 1.79M 122M 1.82M 12.15M 4.77M 60.82M 4.8M 4.69M 202M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news : NeuBase Therapeutics, Inc.

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
27/06/24	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
29/05/24	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	01/11/2021

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	04/01/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-3.20%	-.--%	-	-	1.39M
LONZA GROUP AG	+2.01%	+2.92%	+5.24%	+18.03%	48.7B
REVOLUTION MEDICINES, INC.	+0.26%	+2.93%	+439.43%	+533.80%	42.05B
IQVIA HOLDINGS INC.	-1.53%	-2.25%	+30.95%	+7.15%	38.26B
BEONE MEDICINES AG	+0.69%	+2.40%	+10.48%	+63.05%	37.5B
CELLTRION, INC.	+2.47%	+2.63%	+14.71%	+48.37%	31.44B
MEDPACE HOLDINGS, INC.	-0.47%	+1.16%	+35.93%	+126.09%	16.33B
ASCENDIS PHARMA A/S	+2.31%	-0.49%	-	-	16.47B
EUROFINS SCIENTIFIC SE	+0.80%	+3.29%	+7.15%	+19.89%	13.98B
ICON PUBLIC LIMITED COMPANY	-1.43%	-2.63%	+3.70%	-36.38%	12.43B
Average	+0.18%	+0.76%	+68.45%	+97.50%	28.57B
Weighted average by Cap.	+0.68%	+0.94%	+89.35%	+122.02%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company